Trial Information

Summary: Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P, Antihemophilic Factor/Von Willebrand Factor Complex)

The purpose of this study is to test the safety and effectiveness of Humate-P, a drug that is not approved by the Food & Drug Administration (FDA) for the treatment of patients with congenital (existing at birth) von Willebrand Disease (vWD), an inherited bleeding disorder, in surgery.

Humate-P is currently approved by the FDA (Food and Drug Administration) in the United States for the treatment of Hemophilia A and for the treatment or prevention of bleeding in vWD patients.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

You must have a diagnosis of a vonWillebrand Disease (vWD). There is no age limit to enroll in the study and you must be having elective surgery requiring Humate-P to control the bleeding.

Emergency surgery and a history of allergic reaction to Humate-P.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.